
Hodgkin Lymphoma (B-Cell Hodgkin Lymphoma) Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players, 2022 Update
Description
Hodgkin Lymphoma (B-Cell Hodgkin Lymphoma) Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players, 2022 Update
Summary
Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Hodgkin Lymphoma - Drugs In Development, 2022, provides an overview of the Hodgkin Lymphoma (Oncology) pipeline landscape.
Hodgkin lymphoma is a cancer that starts in white blood cells called lymphocytes. Symptoms include painless swelling of the lymph nodes in the neck, armpits, or groin, fever and chills, night sweats, weight loss, loss of appetite and itchy skin. Hodgkin lymphoma is most common among people ages 15 to 35 and 50 to 70. Past infection with the Epstein-Barr virus (EBV) and HIV infection are at increased risk compared to the general population. Treatment includes surgery, radiation therapy and chemotherapy.
Report Highlights
Global Markets Direct's Pharmaceutical and Healthcare latest pipeline guide Hodgkin Lymphoma - Drugs In Development, 2022, provides comprehensive information on the therapeutics under development for Hodgkin Lymphoma (Oncology), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.
The Hodgkin Lymphoma (Oncology) pipeline guide also reviews of key players involved in therapeutic development for Hodgkin Lymphoma (B-Cell Hodgkin Lymphoma) and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Pre-Registration, Phase III, Phase II, Phase I, IND/CTA Filed, Preclinical, Discovery and Unknown stages are 2, 3, 53, 44, 5, 21, 4 and 2 respectively. Similarly, the Universities portfolio in Phase II, Phase I, Phase 0, Preclinical and Discovery stages comprises 7, 4, 3, 3 and 1 molecules, respectively.
Hodgkin Lymphoma (Oncology) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Global Markets Direct’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.
Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.
Scope
Summary
Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Hodgkin Lymphoma - Drugs In Development, 2022, provides an overview of the Hodgkin Lymphoma (Oncology) pipeline landscape.
Hodgkin lymphoma is a cancer that starts in white blood cells called lymphocytes. Symptoms include painless swelling of the lymph nodes in the neck, armpits, or groin, fever and chills, night sweats, weight loss, loss of appetite and itchy skin. Hodgkin lymphoma is most common among people ages 15 to 35 and 50 to 70. Past infection with the Epstein-Barr virus (EBV) and HIV infection are at increased risk compared to the general population. Treatment includes surgery, radiation therapy and chemotherapy.
Report Highlights
Global Markets Direct's Pharmaceutical and Healthcare latest pipeline guide Hodgkin Lymphoma - Drugs In Development, 2022, provides comprehensive information on the therapeutics under development for Hodgkin Lymphoma (Oncology), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.
The Hodgkin Lymphoma (Oncology) pipeline guide also reviews of key players involved in therapeutic development for Hodgkin Lymphoma (B-Cell Hodgkin Lymphoma) and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Pre-Registration, Phase III, Phase II, Phase I, IND/CTA Filed, Preclinical, Discovery and Unknown stages are 2, 3, 53, 44, 5, 21, 4 and 2 respectively. Similarly, the Universities portfolio in Phase II, Phase I, Phase 0, Preclinical and Discovery stages comprises 7, 4, 3, 3 and 1 molecules, respectively.
Hodgkin Lymphoma (Oncology) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Global Markets Direct’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.
Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.
Scope
- The pipeline guide provides a snapshot of the global therapeutic landscape of Hodgkin Lymphoma (Oncology).
- The pipeline guide reviews pipeline therapeutics for Hodgkin Lymphoma (Oncology) by companies and universities/research institutes based on information derived from company and industry-specific sources.
- The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
- The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
- The pipeline guide reviews key companies involved in Hodgkin Lymphoma (Oncology) therapeutics and enlists all their major and minor projects.
- The pipeline guide evaluates Hodgkin Lymphoma (Oncology) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
- The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
- The pipeline guide reviews latest news related to pipeline therapeutics for Hodgkin Lymphoma (Oncology)
- Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
- Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
- Find and recognize significant and varied types of therapeutics under development for Hodgkin Lymphoma (Oncology).
- Classify potential new clients or partners in the target demographic.
- Develop tactical initiatives by understanding the focus areas of leading companies.
- Plan mergers and acquisitions meritoriously by identifying key players and it’s most promising pipeline therapeutics.
- Formulate corrective measures for pipeline projects by understanding Hodgkin Lymphoma (Oncology) pipeline depth and focus of Indication therapeutics.
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
- Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.
Table of Contents
504 Pages
- Introduction
- Global Markets Direct Report Coverage
- Hodgkin Lymphoma (B-Cell Hodgkin Lymphoma) – Overview
- Hodgkin Lymphoma (B-Cell Hodgkin Lymphoma) – Therapeutics Development
- Pipeline Overview
- Pipeline by Companies
- Pipeline by Universities/Institutes
- Products under Development by Companies
- Products under Development by Universities/Institutes
- Hodgkin Lymphoma (B-Cell Hodgkin Lymphoma) – Therapeutics Assessment
- Assessment by Target
- Assessment by Mechanism of Action
- Assessment by Route of Administration
- Assessment by Molecule Type
- Hodgkin Lymphoma (B-Cell Hodgkin Lymphoma) – Companies Involved in Therapeutics Development
- A. Menarini Industrie Farmaceutiche Riunite Srl
- AbbVie Inc
- ADC Therapeutics SA
- Adlai Nortye Biopharma Co Ltd
- Affimed GmbH
- Alfasigma SpA
- Angiocrine Bioscience Inc
- Apollomics Inc
- Astellas Pharma Inc
- AstraZeneca Plc
- Aurigene Discovery Technologies Ltd
- Avipep Pty Ltd
- Bayer AG
- BeiGene Ltd
- Bio-Path Holdings Inc
- Biohaven Pharmaceutical Holding Company Ltd
- Bristol-Myers Squibb Co
- Carrick Therapeutics Ltd
- Catalent Inc
- Cellectar Biosciences Inc
- Cellectis SA
- Celleron Therapeutics Ltd
- Cellestia Biotech AG
- Cellular Biomedicine Group Inc
- Celularity Inc
- Checkmate Pharmaceuticals Inc
- Checkpoint Therapeutics Inc
- Chimeric Therapeutics Ltd
- CSL Ltd
- CStone Pharmaceuticals Co Ltd
- Curis Inc
- Daiichi Sankyo Co Ltd
- Dyadic International Inc
- Eutilex Co Ltd
- Faron Pharmaceuticals Oy
- Genentech USA Inc
- Gibson Oncology LLC
- Gilead Sciences Inc
- Glenmark Pharmaceuticals Ltd
- Guangzhou Sinogen Pharmaceutical Co Ltd
- Hangzhou Sumgen Biotech Co Ltd
- Harbin Gloria Pharmaceuticals Co Ltd
- Hebei Senlang Biotechnology Co Ltd
- Helocyte Biosciences Inc
- HRAIN Biotechnology Co Ltd
- Hutchison MediPharma Ltd
- Immune Cell Inc
- ImmuneOnco Biopharmaceuticals (Shanghai) Co Ltd
- Incyte Corp
- Inhibrx Inc
- Innovent Biologics Inc
- Intellia Therapeutics Inc
- Kymera Therapeutics Inc
- LegoChem Biosciences Inc
- Luye Pharma Group Ltd
- Magenta Therapeutics Inc
- Marker Therapeutics Inc
- MediSix Therapeutics Pte Ltd
- Merck & Co Inc
- Merck KGaA
- Millennium Pharmaceuticals Inc
- Miltenyi Biotec BV & Co KG
- Mirati Therapeutics Inc
- NewBio Therapeutics Inc
- Northlake International LLC
- OncoTartis Inc
- Ono Pharmaceutical Co Ltd
- Pfizer Inc
- PlantForm Corp
- Protheragen Inc
- Rafael Pharmaceuticals Inc
- RAPT Therapeutics Inc
- Regeneron Pharmaceuticals Inc
- Rhizen Pharmaceuticals SA
- Rich Pharmaceuticals Inc
- Rizen (Suzhou) Biosciences Co Ltd
- Sanofi
- Seagen Inc
- Shanghai First Song Therapeutics Co Ltd
- Shanghai Fudan-Zhangjiang Bio-Pharmaceutical Co Ltd
- Shanghai Junshi Bioscience Co Ltd
- Shanghai Pharmaceutical Group Co Ltd
- Shanghai Pharmaceuticals Holding Co Ltd
- Shanghai Unicar-Therapy Bio-Medicine Technology Co Ltd
- Shanghai YaKe Biotechnology Co Ltd
- Shattuck Labs Inc
- Shenzhen Chipscreen Biosciences Co Ltd
- Sichuan Kelun Pharmaceutical Co Ltd
- SpecificiT Pharma Inc
- Suzhou Everhealth Biomedical Co Ltd
- Syndax Pharmaceuticals Inc
- Tacitus Therapeutics Inc
- Takeda Pharmaceutical Co Ltd
- Tessa Therapeutics Ltd
- Tevogen Bio Inc
- Tubulis GmbH
- Tyme Inc
- Vincerx Pharma Inc
- Viracta Therapeutics Inc
- Waterstone Hanxbio Pty Ltd
- Wuhan Bio-Raid Biotechnology Co Ltd
- Xencor Inc
- Hodgkin Lymphoma (B-Cell Hodgkin Lymphoma) – Drug Profiles
- (nivolumab + relatlimab) – Drug Profile
- (pembrolizumab+vibostolimab) – Drug Profile
- AB-205 – Drug Profile
- acalabrutinib maleate – Drug Profile
- ADCAVP-10 – Drug Profile
- AFM-13 – Drug Profile
- amdizalisib – Drug Profile
- AN-4005 – Drug Profile
- Antibody to Inhibit PD-L1 for Oncology – Drug Profile
- APL-502 – Drug Profile
- avelumab – Drug Profile
- AZD-4573 – Drug Profile
- AZD-7789 – Drug Profile
- B-006 – Drug Profile
- bendamustine hydrochloride – Drug Profile
- bexmarilimab – Drug Profile
- BMS-986415 – Drug Profile
- BP-1002 – Drug Profile
- brentuximab vedotin – Drug Profile
- CA-170 – Drug Profile
- CAL-1 – Drug Profile
- camidanlumab tesirine – Drug Profile
- CAT-03106 – Drug Profile
- CAT-12-106 – Drug Profile
- CB-103 – Drug Profile
- CBM-C30.1 – Drug Profile
- CD3XCD20 bsAb – Drug Profile
- Cellular Immunotherapy for Hodgkin Lymphoma and Diffuse Large B Cell Lymphoma – Drug Profile
- Cellular Immunotherapy for Oncology – Drug Profile
- Cellular Immunotherapy to Target CD56 for Oncology – Drug Profile
- Cellular Immunotherapy to Target LMP-1 and LMP-2 for Epstein-Barr Virus Associated Cancers – Drug Profile
- Cellular Immunotherapy to Target NY-ESO-1, MAGEA4, PRAME, Survivin and Synovial Sarcoma X for Oncology – Drug Profile
- cemiplimab – Drug Profile
- CHM-0201 – Drug Profile
- copanlisib hydrochloride – Drug Profile
- cosibelimab – Drug Profile
- CT-900 – Drug Profile
- CTL-19 – Drug Profile
- CXD-101 – Drug Profile
- CYNK-001 – Drug Profile
- devimistat – Drug Profile
- durvalumab – Drug Profile
- durvalumab + tremelimumab – Drug Profile
- EBViNT – Drug Profile
- entinostat – Drug Profile
- enzalutamide – Drug Profile
- F-0002ADC – Drug Profile
- fimepinostat – Drug Profile
- FLX-475 – Drug Profile
- Gene Therapy 1 for Oncology – Drug Profile
- Gene Therapy for Hodgkin Lymphoma, Non Hodgkin's Lymphoma and Plasma Cell Neoplasm – Drug Profile
- Gene Therapy to Target CD19 and CD30 for Hodgkin Lymphoma – Drug Profile
- Gene Therapy to Target CD19 for Oncology – Drug Profile
- Gene Therapy to Target CD30 and CCR4 for Hodgkin and Non-Hodgkin Lymphomas – Drug Profile
- Gene Therapy to Target CD30 for Blood Cancer – Drug Profile
- Gene Therapy to Target CD30 for Blood Cancers – Drug Profile
- Gene Therapy to Target CD30 for Hodgkin Lymphoma – Drug Profile
- Gene Therapy to Target CD30 for Hodgkin Lymphoma and Anaplastic Large Cell Lymphoma – Drug Profile
- Gene Therapy to Target CD30 for Hodgkin Lymphoma and Peripheral T-Cell Lymphoma – Drug Profile
- Gene Therapy to Target CD30 for Hodgkin''s Lymphoma – Drug Profile
- Gene Therapy to Target CD30 for Lymphoproliferative Disorders – Drug Profile
- Gene Therapy to Target CD30 for Oncology – Drug Profile
- Gene Therapy to Target GM-CSF for Chronic Lymphocytic Leukemia and Hodgkin Lymphoma – Drug Profile
- Gene Therapy to Target LMP1 for Epstein–Barr Virus (HHV-4) Infections and Oncology – Drug Profile
- Gene-Modified Cell Therapy to Target CD30 for Oncology – Drug Profile
- geptanolimab – Drug Profile
- GRC-54276 – Drug Profile
- HRAIN-009 – Drug Profile
- HSC-100 – Drug Profile
- HX-009 – Drug Profile
- iberdomide hydrochloride – Drug Profile
- ibrutinib – Drug Profile
- IMM-01 – Drug Profile
- IMMU-140 – Drug Profile
- INBRX-105 – Drug Profile
- iopofosine i-131 – Drug Profile
- ipilimumab – Drug Profile
- ipilimumab + nivolumab – Drug Profile
- itacitinib adipate – Drug Profile
- ixazomib citrate – Drug Profile
- JS-004 – Drug Profile
- JS-105 – Drug Profile
- KLA-167 – Drug Profile
- KT-333 – Drug Profile
- LCB-71 – Drug Profile
- LMP-400 – Drug Profile
- magrolimab – Drug Profile
- MEN-1703 – Drug Profile
- MK-4280 – Drug Profile
- mocetinostat – Drug Profile
- Monoclonal Antibody Conjugate to Target TNFRSF8 for Oncology – Drug Profile
- Monoclonal Antibody to Inhibit TIM-3 for Oncology – Drug Profile
- nanatinostat – Drug Profile
- NBT-528 – Drug Profile
- nivolumab – Drug Profile
- nivolumab biosimilar – Drug Profile
- NTLA-6001 – Drug Profile
- odronextamab – Drug Profile
- olaparib – Drug Profile
- OT-82 – Drug Profile
- parsaclisib – Drug Profile
- PCART-30 – Drug Profile
- pembrolizumab – Drug Profile
- pembrolizumab biosimilar – Drug Profile
- PF-07901801 – Drug Profile
- polatuzumab vedotin – Drug Profile
- procarbazine hydrochloride – Drug Profile
- racemetyrosine – Drug Profile
- relatlimab – Drug Profile
- ricolinostat – Drug Profile
- RP-323 – Drug Profile
- ruxolitinib phosphate – Drug Profile
- SAR-444245 – Drug Profile
- SEA-CD40 – Drug Profile
- SENL-001 – Drug Profile
- SG-2501 – Drug Profile
- SGN-1 – Drug Profile
- SGN-TGT – Drug Profile
- sintilimab – Drug Profile
- SL-279252 – Drug Profile
- SL-501 – Drug Profile
- Small Molecule to Inhibit ADAM-10 for Hodgkin Lymphoma – Drug Profile
- spanlecortemlocel – Drug Profile
- subasumstat – Drug Profile
- sugemalimab – Drug Profile
- tenalisib – Drug Profile
- tinostamustine – Drug Profile
- tislelizumab – Drug Profile
- toripalimab – Drug Profile
- Triplex – Drug Profile
- troriluzole hydrochloride – Drug Profile
- TT-11 – Drug Profile
- TT-11X – Drug Profile
- TTI-621 – Drug Profile
- TUB-010 – Drug Profile
- tucidinostat – Drug Profile
- UCART-123 – Drug Profile
- Vaccine for EBV Associated Nasopharyngeal Cancer and Hodgkin Lymphoma – Drug Profile
- valemetostat – Drug Profile
- vidutolimod – Drug Profile
- VIP-943 – Drug Profile
- vorinostat – Drug Profile
- VSV-CD30 – Drug Profile
- vudalimab – Drug Profile
- zimberelimab – Drug Profile
- Hodgkin Lymphoma (B-Cell Hodgkin Lymphoma) – Dormant Projects
- Hodgkin Lymphoma (B-Cell Hodgkin Lymphoma) – Discontinued Products
- Hodgkin Lymphoma (B-Cell Hodgkin Lymphoma) – Product Development Milestones
- Featured News & Press Releases
- Apr 11, 2022: Glenmark Specialty S.A. receives approval for conducting phase 1 clinical trial of its novel molecule GRC 54276 in patients with advanced solid tumors and Hodgkin's lymphoma
- Apr 10, 2022: Affimed presents updated clinical data from phase 1/2 study of AFM13 precomplexed with cord blood-derived NK cells at AACR Annual Meeting
- Dec 14, 2021: Tessa Therapeutics announces positive data from phase 2 trial of autologous CD30-CAR-T therapy (TT11) in relapsed or refractory classical hodgkin lymphoma at 2021 ASH Annual Meeting
- Dec 12, 2021: Seagen announces preliminary results from phase 2 clinical trial of ADCETRIS (brentuximab vedotin) in novel combination of agents for patients with advanced stage classical hodgkin lymphoma
- Dec 09, 2021: Affimed to host virtual investor call today to discuss treatment of CD30-positive lymphoma patients with cord blood-derived natural killer cells pre-complexed with innate cell engager AFM13
- Dec 02, 2021: BeiGene announces inclusion in the China National Reimbursement Drug List (NRDL) of Tislelizumab in three new indications
- Dec 02, 2021: Innovent and Lilly announce successful expansion of Sintilimab in China National Reimbursement Drug List to include three additional first-line indications
- Nov 04, 2021: Seagen to highlight multiple ADCETRIS (brentuximab vedotin) data presentations at the upcoming 2021 American Society of Hematology (ASH) Annual Meeting
- Nov 03, 2021: Tessa Therapeutics announces presentation of autologous cell therapy data at 2021 ASH Annual Meeting
- Sep 27, 2021: ONO receives approval of Opdivo (nivolumab) for dosage and administration for treatment of Pediatric Patients with Recurrent or Refractory Classical Hodgkin Lymphoma in Japan
- Aug 30, 2021: Ligand’s partner Gloria Biosciences receives approval in China for zimberelimab for the treatment of recurrent or refractory classical Hodgkin’s lymphoma
- Jun 22, 2021: ADC Therapeutics announces encouraging interim results from pivotal phase 2 clinical trial of Camidanlumab Tesirine (Cami) presented at the 16th Annual International Conference on Malignant Lymphoma
- Jun 09, 2021: ADC Therapeutics announces presentation on Camidanlumab at the 16th Annual International Conference on Malignant Lymphoma
- May 26, 2021: ADC Therapeutics announces online publication of Camidanlumab Tesirine phase 1 results in The Lancet Haematology
- May 14, 2021: Tessa Therapeutics announces positive, topline data from ongoing phase 1 trial of allogeneic, “Off-the-Shelf” cell therapy, in patients with relapsed or refractory CD30-positive lymphoma
- Appendix
- Methodology
- Coverage
- Secondary Research
- Primary Research
- Expert Panel Validation
- Contact Us
- Disclaimer
- List of Tables
- Table 1: Number of Products under Development for Hodgkin Lymphoma (B-Cell Hodgkin Lymphoma), 2022
- Table 2: Number of Products under Development by Companies, 2022
- Table 3: Number of Products under Development by Companies, 2022 (Contd..1)
- Table 4: Number of Products under Development by Companies, 2022 (Contd..2)
- Table 5: Number of Products under Development by Companies, 2022 (Contd..3)
- Table 6: Number of Products under Development by Companies, 2022 (Contd..4)
- Table 7: Number of Products under Development by Universities/Institutes, 2022
- Table 8: Products under Development by Companies, 2022
- Table 9: Products under Development by Companies, 2022 (Contd..1)
- Table 10: Products under Development by Companies, 2022 (Contd..2)
- Table 11: Products under Development by Companies, 2022 (Contd..3)
- Table 12: Products under Development by Companies, 2022 (Contd..4)
- Table 13: Products under Development by Companies, 2022 (Contd..5)
- Table 14: Products under Development by Companies, 2022 (Contd..6)
- Table 15: Products under Development by Companies, 2022 (Contd..7)
- Table 16: Products under Development by Universities/Institutes, 2022
- Table 17: Number of Products by Stage and Target, 2022
- Table 18: Number of Products by Stage and Target, 2022 (Contd..1)
- Table 19: Number of Products by Stage and Target, 2022 (Contd..2)
- Table 20: Number of Products by Stage and Target, 2022 (Contd..3)
- Table 21: Number of Products by Stage and Mechanism of Action, 2022
- Table 22: Number of Products by Stage and Mechanism of Action, 2022 (Contd..1)
- Table 23: Number of Products by Stage and Mechanism of Action, 2022 (Contd..2)
- Table 24: Number of Products by Stage and Mechanism of Action, 2022 (Contd..3)
- Table 25: Number of Products by Stage and Route of Administration, 2022
- Table 26: Number of Products by Stage and Molecule Type, 2022
- Table 27: Hodgkin Lymphoma (B-Cell Hodgkin Lymphoma) – Pipeline by A. Menarini Industrie Farmaceutiche Riunite Srl, 2022
- Table 28: Hodgkin Lymphoma (B-Cell Hodgkin Lymphoma) – Pipeline by AbbVie Inc, 2022
- Table 29: Hodgkin Lymphoma (B-Cell Hodgkin Lymphoma) – Pipeline by ADC Therapeutics SA, 2022
- Table 30: Hodgkin Lymphoma (B-Cell Hodgkin Lymphoma) – Pipeline by Adlai Nortye Biopharma Co Ltd, 2022
- Table 31: Hodgkin Lymphoma (B-Cell Hodgkin Lymphoma) – Pipeline by Affimed GmbH, 2022
- Table 32: Hodgkin Lymphoma (B-Cell Hodgkin Lymphoma) – Pipeline by Alfasigma SpA, 2022
- Table 33: Hodgkin Lymphoma (B-Cell Hodgkin Lymphoma) – Pipeline by Angiocrine Bioscience Inc, 2022
- Table 34: Hodgkin Lymphoma (B-Cell Hodgkin Lymphoma) – Pipeline by Apollomics Inc, 2022
- Table 35: Hodgkin Lymphoma (B-Cell Hodgkin Lymphoma) – Pipeline by Astellas Pharma Inc, 2022
- Table 36: Hodgkin Lymphoma (B-Cell Hodgkin Lymphoma) – Pipeline by AstraZeneca Plc, 2022
- Table 37: Hodgkin Lymphoma (B-Cell Hodgkin Lymphoma) – Pipeline by Aurigene Discovery Technologies Ltd, 2022
- Table 38: Hodgkin Lymphoma (B-Cell Hodgkin Lymphoma) – Pipeline by Avipep Pty Ltd, 2022
- Table 39: Hodgkin Lymphoma (B-Cell Hodgkin Lymphoma) – Pipeline by Bayer AG, 2022
- Table 40: Hodgkin Lymphoma (B-Cell Hodgkin Lymphoma) – Pipeline by BeiGene Ltd, 2022
- Table 41: Hodgkin Lymphoma (B-Cell Hodgkin Lymphoma) – Pipeline by Bio-Path Holdings Inc, 2022
- Table 42: Hodgkin Lymphoma (B-Cell Hodgkin Lymphoma) – Pipeline by Biohaven Pharmaceutical Holding Company Ltd, 2022
- Table 43: Hodgkin Lymphoma (B-Cell Hodgkin Lymphoma) – Pipeline by Bristol-Myers Squibb Co, 2022
- Table 44: Hodgkin Lymphoma (B-Cell Hodgkin Lymphoma) – Pipeline by Carrick Therapeutics Ltd, 2022
- Table 45: Hodgkin Lymphoma (B-Cell Hodgkin Lymphoma) – Pipeline by Catalent Inc, 2022
- Table 46: Hodgkin Lymphoma (B-Cell Hodgkin Lymphoma) – Pipeline by Cellectar Biosciences Inc, 2022
- Table 47: Hodgkin Lymphoma (B-Cell Hodgkin Lymphoma) – Pipeline by Cellectis SA, 2022
- Table 48: Hodgkin Lymphoma (B-Cell Hodgkin Lymphoma) – Pipeline by Celleron Therapeutics Ltd, 2022
- Table 49: Hodgkin Lymphoma (B-Cell Hodgkin Lymphoma) – Pipeline by Cellestia Biotech AG, 2022
- Table 50: Hodgkin Lymphoma (B-Cell Hodgkin Lymphoma) – Pipeline by Cellular Biomedicine Group Inc, 2022
- Table 51: Hodgkin Lymphoma (B-Cell Hodgkin Lymphoma) – Pipeline by Celularity Inc, 2022
- Table 52: Hodgkin Lymphoma (B-Cell Hodgkin Lymphoma) – Pipeline by Checkmate Pharmaceuticals Inc, 2022
- Table 53: Hodgkin Lymphoma (B-Cell Hodgkin Lymphoma) – Pipeline by Checkpoint Therapeutics Inc, 2022
- Table 54: Hodgkin Lymphoma (B-Cell Hodgkin Lymphoma) – Pipeline by Chimeric Therapeutics Ltd, 2022
- Table 55: Hodgkin Lymphoma (B-Cell Hodgkin Lymphoma) – Pipeline by CSL Ltd, 2022
- Table 56: Hodgkin Lymphoma (B-Cell Hodgkin Lymphoma) – Pipeline by CStone Pharmaceuticals Co Ltd, 2022
- Table 57: Hodgkin Lymphoma (B-Cell Hodgkin Lymphoma) – Pipeline by Curis Inc, 2022
- Table 58: Hodgkin Lymphoma (B-Cell Hodgkin Lymphoma) – Pipeline by Daiichi Sankyo Co Ltd, 2022
- Table 59: Hodgkin Lymphoma (B-Cell Hodgkin Lymphoma) – Pipeline by Dyadic International Inc, 2022
- Table 60: Hodgkin Lymphoma (B-Cell Hodgkin Lymphoma) – Pipeline by Eutilex Co Ltd, 2022
- Table 61: Hodgkin Lymphoma (B-Cell Hodgkin Lymphoma) – Pipeline by Faron Pharmaceuticals Oy, 2022
- Table 62: Hodgkin Lymphoma (B-Cell Hodgkin Lymphoma) – Pipeline by Genentech USA Inc, 2022
- Table 63: Hodgkin Lymphoma (B-Cell Hodgkin Lymphoma) – Pipeline by Gibson Oncology LLC, 2022
- Table 64: Hodgkin Lymphoma (B-Cell Hodgkin Lymphoma) – Pipeline by Gilead Sciences Inc, 2022
- Table 65: Hodgkin Lymphoma (B-Cell Hodgkin Lymphoma) – Pipeline by Glenmark Pharmaceuticals Ltd, 2022
- Table 66: Hodgkin Lymphoma (B-Cell Hodgkin Lymphoma) – Pipeline by Guangzhou Sinogen Pharmaceutical Co Ltd, 2022
- Table 67: Hodgkin Lymphoma (B-Cell Hodgkin Lymphoma) – Pipeline by Hangzhou Sumgen Biotech Co Ltd, 2022
- Table 68: Hodgkin Lymphoma (B-Cell Hodgkin Lymphoma) – Pipeline by Harbin Gloria Pharmaceuticals Co Ltd, 2022
- Table 69: Hodgkin Lymphoma (B-Cell Hodgkin Lymphoma) – Pipeline by Hebei Senlang Biotechnology Co Ltd, 2022
- Table 70: Hodgkin Lymphoma (B-Cell Hodgkin Lymphoma) – Pipeline by Helocyte Biosciences Inc, 2022
- Table 71: Hodgkin Lymphoma (B-Cell Hodgkin Lymphoma) – Pipeline by HRAIN Biotechnology Co Ltd, 2022
- Table 72: Hodgkin Lymphoma (B-Cell Hodgkin Lymphoma) – Pipeline by Hutchison MediPharma Ltd, 2022
- Table 73: Hodgkin Lymphoma (B-Cell Hodgkin Lymphoma) – Pipeline by Immune Cell Inc, 2022
- Table 74: Hodgkin Lymphoma (B-Cell Hodgkin Lymphoma) – Pipeline by ImmuneOnco Biopharmaceuticals (Shanghai) Co Ltd, 2022
- Table 75: Hodgkin Lymphoma (B-Cell Hodgkin Lymphoma) – Pipeline by Incyte Corp, 2022
- Table 76: Hodgkin Lymphoma (B-Cell Hodgkin Lymphoma) – Pipeline by Inhibrx Inc, 2022
- Table 77: Hodgkin Lymphoma (B-Cell Hodgkin Lymphoma) – Pipeline by Innovent Biologics Inc, 2022
- Table 78: Hodgkin Lymphoma (B-Cell Hodgkin Lymphoma) – Pipeline by Intellia Therapeutics Inc, 2022
- Table 79: Hodgkin Lymphoma (B-Cell Hodgkin Lymphoma) – Pipeline by Kymera Therapeutics Inc, 2022
- Table 80: Hodgkin Lymphoma (B-Cell Hodgkin Lymphoma) – Pipeline by LegoChem Biosciences Inc, 2022
- Table 81: Hodgkin Lymphoma (B-Cell Hodgkin Lymphoma) – Pipeline by Luye Pharma Group Ltd, 2022
- Table 82: Hodgkin Lymphoma (B-Cell Hodgkin Lymphoma) – Pipeline by Magenta Therapeutics Inc, 2022
- Table 83: Hodgkin Lymphoma (B-Cell Hodgkin Lymphoma) – Pipeline by Marker Therapeutics Inc, 2022
- Table 84: Hodgkin Lymphoma (B-Cell Hodgkin Lymphoma) – Pipeline by MediSix Therapeutics Pte Ltd, 2022
- Table 85: Hodgkin Lymphoma (B-Cell Hodgkin Lymphoma) – Pipeline by Merck & Co Inc, 2022
- Table 86: Hodgkin Lymphoma (B-Cell Hodgkin Lymphoma) – Pipeline by Merck KGaA, 2022
- Table 87: Hodgkin Lymphoma (B-Cell Hodgkin Lymphoma) – Pipeline by Millennium Pharmaceuticals Inc, 2022
- Table 88: Hodgkin Lymphoma (B-Cell Hodgkin Lymphoma) – Pipeline by Miltenyi Biotec BV & Co KG, 2022
- Table 89: Hodgkin Lymphoma (B-Cell Hodgkin Lymphoma) – Pipeline by Mirati Therapeutics Inc, 2022
- Table 90: Hodgkin Lymphoma (B-Cell Hodgkin Lymphoma) – Pipeline by NewBio Therapeutics Inc, 2022
- Table 91: Hodgkin Lymphoma (B-Cell Hodgkin Lymphoma) – Pipeline by Northlake International LLC, 2022
- Table 92: Hodgkin Lymphoma (B-Cell Hodgkin Lymphoma) – Pipeline by OncoTartis Inc, 2022
- Table 93: Hodgkin Lymphoma (B-Cell Hodgkin Lymphoma) – Pipeline by Ono Pharmaceutical Co Ltd, 2022
- Table 94: Hodgkin Lymphoma (B-Cell Hodgkin Lymphoma) – Pipeline by Pfizer Inc, 2022
- Table 95: Hodgkin Lymphoma (B-Cell Hodgkin Lymphoma) – Pipeline by PlantForm Corp, 2022
- Table 96: Hodgkin Lymphoma (B-Cell Hodgkin Lymphoma) – Pipeline by Protheragen Inc, 2022
- Table 97: Hodgkin Lymphoma (B-Cell Hodgkin Lymphoma) – Pipeline by Rafael Pharmaceuticals Inc, 2022
- Table 98: Hodgkin Lymphoma (B-Cell Hodgkin Lymphoma) – Pipeline by RAPT Therapeutics Inc, 2022
- Table 99: Hodgkin Lymphoma (B-Cell Hodgkin Lymphoma) – Pipeline by Regeneron Pharmaceuticals Inc, 2022
- Table 100: Hodgkin Lymphoma (B-Cell Hodgkin Lymphoma) – Pipeline by Rhizen Pharmaceuticals SA, 2022
- Table 101: Hodgkin Lymphoma (B-Cell Hodgkin Lymphoma) – Pipeline by Rich Pharmaceuticals Inc, 2022
- Table 102: Hodgkin Lymphoma (B-Cell Hodgkin Lymphoma) – Pipeline by Rizen (Suzhou) Biosciences Co Ltd, 2022
- Table 103: Hodgkin Lymphoma (B-Cell Hodgkin Lymphoma) – Pipeline by Sanofi, 2022
- Table 104: Hodgkin Lymphoma (B-Cell Hodgkin Lymphoma) – Pipeline by Seagen Inc, 2022
- Table 105: Hodgkin Lymphoma (B-Cell Hodgkin Lymphoma) – Pipeline by Shanghai First Song Therapeutics Co Ltd, 2022
- Table 106: Hodgkin Lymphoma (B-Cell Hodgkin Lymphoma) – Pipeline by Shanghai Fudan-Zhangjiang Bio-Pharmaceutical Co Ltd, 2022
- Table 107: Hodgkin Lymphoma (B-Cell Hodgkin Lymphoma) – Pipeline by Shanghai Junshi Bioscience Co Ltd, 2022
- Table 108: Hodgkin Lymphoma (B-Cell Hodgkin Lymphoma) – Pipeline by Shanghai Pharmaceutical Group Co Ltd, 2022
- Table 109: Hodgkin Lymphoma (B-Cell Hodgkin Lymphoma) – Pipeline by Shanghai Pharmaceuticals Holding Co Ltd, 2022
- Table 110: Hodgkin Lymphoma (B-Cell Hodgkin Lymphoma) – Pipeline by Shanghai Unicar-Therapy Bio-Medicine Technology Co Ltd, 2022
- Table 111: Hodgkin Lymphoma (B-Cell Hodgkin Lymphoma) – Pipeline by Shanghai YaKe Biotechnology Co Ltd, 2022
- Table 112: Hodgkin Lymphoma (B-Cell Hodgkin Lymphoma) – Pipeline by Shattuck Labs Inc, 2022
- Table 113: Hodgkin Lymphoma (B-Cell Hodgkin Lymphoma) – Pipeline by Shenzhen Chipscreen Biosciences Co Ltd, 2022
- Table 114: Hodgkin Lymphoma (B-Cell Hodgkin Lymphoma) – Pipeline by Sichuan Kelun Pharmaceutical Co Ltd, 2022
- Table 115: Hodgkin Lymphoma (B-Cell Hodgkin Lymphoma) – Pipeline by SpecificiT Pharma Inc, 2022
- Table 116: Hodgkin Lymphoma (B-Cell Hodgkin Lymphoma) – Pipeline by Suzhou Everhealth Biomedical Co Ltd, 2022
- Table 117: Hodgkin Lymphoma (B-Cell Hodgkin Lymphoma) – Pipeline by Syndax Pharmaceuticals Inc, 2022
- Table 118: Hodgkin Lymphoma (B-Cell Hodgkin Lymphoma) – Pipeline by Tacitus Therapeutics Inc, 2022
- Table 119: Hodgkin Lymphoma (B-Cell Hodgkin Lymphoma) – Pipeline by Takeda Pharmaceutical Co Ltd, 2022
- Table 120: Hodgkin Lymphoma (B-Cell Hodgkin Lymphoma) – Pipeline by Tessa Therapeutics Ltd, 2022
- Table 121: Hodgkin Lymphoma (B-Cell Hodgkin Lymphoma) – Pipeline by Tevogen Bio Inc, 2022
- Table 122: Hodgkin Lymphoma (B-Cell Hodgkin Lymphoma) – Pipeline by Tubulis GmbH, 2022
- Table 123: Hodgkin Lymphoma (B-Cell Hodgkin Lymphoma) – Pipeline by Tyme Inc, 2022
- Table 124: Hodgkin Lymphoma (B-Cell Hodgkin Lymphoma) – Pipeline by Vincerx Pharma Inc, 2022
- Table 125: Hodgkin Lymphoma (B-Cell Hodgkin Lymphoma) – Pipeline by Viracta Therapeutics Inc, 2022
- Table 126: Hodgkin Lymphoma (B-Cell Hodgkin Lymphoma) – Pipeline by Waterstone Hanxbio Pty Ltd, 2022
- Table 127: Hodgkin Lymphoma (B-Cell Hodgkin Lymphoma) – Pipeline by Wuhan Bio-Raid Biotechnology Co Ltd, 2022
- Table 128: Hodgkin Lymphoma (B-Cell Hodgkin Lymphoma) – Pipeline by Xencor Inc, 2022
- Table 129: Hodgkin Lymphoma (B-Cell Hodgkin Lymphoma) – Dormant Projects, 2022
- Table 130: Hodgkin Lymphoma (B-Cell Hodgkin Lymphoma) – Dormant Projects, 2022 (Contd..1)
- Table 131: Hodgkin Lymphoma (B-Cell Hodgkin Lymphoma) – Dormant Projects, 2022 (Contd..2)
- Table 132: Hodgkin Lymphoma (B-Cell Hodgkin Lymphoma) – Dormant Projects, 2022 (Contd..3)
- Table 133: Hodgkin Lymphoma (B-Cell Hodgkin Lymphoma) – Dormant Projects, 2022 (Contd..4)
- Table 134: Hodgkin Lymphoma (B-Cell Hodgkin Lymphoma) – Discontinued Products, 2022
- List of Figures
- Figure 1: Number of Products under Development for Hodgkin Lymphoma (B-Cell Hodgkin Lymphoma), 2022
- Figure 2: Number of Products under Development by Companies, 2022
- Figure 3: Number of Products under Development by Universities/Institutes, 2022
- Figure 4: Number of Products by Top 10 Targets, 2022
- Figure 5: Number of Products by Stage and Top 10 Targets, 2022
- Figure 6: Number of Products by Top 10 Mechanism of Actions, 2022
- Figure 7: Number of Products by Stage and Top 10 Mechanism of Actions, 2022
- Figure 8: Number of Products by Top 10 Routes of Administration, 2022
- Figure 9: Number of Products by Stage and Top 10 Routes of Administration, 2022
- Figure 10: Number of Products by Top 10 Molecule Types, 2022
- Figure 11: Number of Products by Stage and Top 10 Molecule Types, 2022
Pricing
Currency Rates
Questions or Comments?
Our team has the ability to search within reports to verify it suits your needs. We can also help maximize your budget by finding sections of reports you can purchase.